This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nicasio, A. M.
Right arrow Articles by Kuti, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nicasio, A. M.
Right arrow Articles by Kuti, J. L.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2009, p. 1218-1220, Vol. 53, No. 3
0066-4804/09/$08.00+0     doi:10.1128/AAC.01386-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Bronchopulmonary Disposition of Micafungin in Healthy Adult Volunteers{triangledown}

Anthony M. Nicasio,1 Pamela R. Tessier,1 David P. Nicolau,1,2 R. Fredrick Knauft,3 John Russomanno,3 Eric Shore,3 and Joseph L. Kuti1*

Center for Anti-Infective Research and Development,1 Department of Medicine, Division of Infectious Diseases,2 Department of Medicine, Division of Pulmonology, Hartford Hospital, Hartford, Connecticut3

Received 15 October 2008/ Returned for modification 24 November 2008/ Accepted 18 December 2008

By way of bronchoscopy and bronchoalveolar lavage, intrapulmonary steady-state concentrations of micafungin administered at 150 mg daily to 15 healthy volunteers were determined at 4, 12, and 24 h after the third dose. The micafungin disposition was predominantly intracellular, with approximately 106% penetration into alveolar macrophages and 5% penetration into epithelial lining fluid.

* Corresponding author. Mailing address: Center for Anti-Infective Research and Development, Hartford Hospital, 80 Seymour St., Hartford, CT 06102. Phone: (860) 545-3612. Fax: (860) 545-3992. E-mail: jkuti{at}harthosp.org

{triangledown} Published ahead of print on 29 December 2008.

Antimicrobial Agents and Chemotherapy, March 2009, p. 1218-1220, Vol. 53, No. 3
0066-4804/09/$08.00+0     doi:10.1128/AAC.01386-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Crandon, J. L., Banevicius, M. A., Fang, A. F., Crownover, P. H., Knauft, R. F., Pope, J. S., Russomanno, J. H., Shore, E., Nicolau, D. P., Kuti, J. L. (2009). Bronchopulmonary Disposition of Intravenous Voriconazole and Anidulafungin Given in Combination to Healthy Adults. Antimicrob. Agents Chemother. 53: 5102-5107 [Abstract] [Full Text]  
  • Weiler, S., Falkensammer, G., Hammerer-Lercher, A., Anliker, M., Vogelsinger, H., Joannidis, M., Dunzendorfer, S., Stein, M., Bellmann, R. (2009). Pulmonary Epithelial Lining Fluid Concentrations after Use of Systemic Amphotericin B Lipid Formulations. Antimicrob. Agents Chemother. 53: 4934-4937 [Abstract] [Full Text]  
  • Ikawa, K., Nomura, K., Morikawa, N., Ikeda, K., Taniwaki, M. (2009). Assessment of micafungin regimens by pharmacokinetic-pharmacodynamic analysis: a dosing strategy for Aspergillus infections. J Antimicrob Chemother 64: 840-844 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»